New data shows Alzheimer’s patients prefer long-term use of Leqembi with Eisai and Biogen’s insights

Recent findings from Eisai and Biogen reveal that a significant number of Alzheimer’s patients are opting to continue using Leqembi, indicating strong patient satisfaction and efficacy of the treatment. This data highlights the long-term benefits of Leqembi, a drug co-developed by Eisai and Biogen, aimed at slowing the progression of Alzheimer’s disease. The study underscores the increasing importance of effective Alzheimer’s treatments as the global patient population continues to grow. By choosing to remain on Leqembi for extended periods, patients are demonstrating trust in its ability to manage symptoms and improve quality of life. This development not only reinforces Leqembi’s position in the market but also paves the way for further advancements in Alzheimer’s therapies. With ongoing research and positive patient outcomes, Leqembi is set to play a crucial role in future treatment strategies. The new data serves as a testament to the collaborative efforts between Eisai and Biogen in addressing the challenges of Alzheimer’s disease.

PMLiVE